arrhythmias

360 CRT

Keeping heart failure patients out of hospital

It is more important than ever for physicians to monitor and manage their heart failure patients.

Heart Failure diagnostics, battery longevity, and remote management systems from Boston Scientific combine to offer 360-degree clinical care and reduce hospitalizations and hospital visits.

heart failure patients
CRT-D avoidable change

CRT-D avoidable change-outs for patients >70 years old, using a CRT-D with nine-year longevity¹

Patients desire a longer-lasting device

Patients desire a longer-lasting device²

Reduction in hospitalizations associated with HeartLogic™

Reduction in hospitalizations associated with HeartLogic™³

ENDURALIFE

Longevity

The patient's life is improved by longevity by requiring fewer replacements:

  • Assuring that infection and complications are minimized
  • Reducing the cost of therapy
  • Enhancing patient therapy through battery optimization
  • Improving patients' quality of life
ENDURALIFE

EnduraLife™ Battery Technology was introduced by Boston Scientific in 2007 and has been validated by nine studies published since 20134⁴⁻¹³. Boston Scientific offers the longest-lasting devices on the market¹⁴⁻¹⁵.

Thanks to the ENDURALIFE technology, Boston Scientific ICD and CRT-D devices have demonstrated superior battery performance versus comparative devices, when estimated using standardized criteria⁵.

How we compare to our competitors

The 8-year product performance reports show that CRT-Ds with Enduralife Technology have greater longevity than comparable devices.¹⁷⁻¹⁸

BOSTON SCIENTIFIC CRT-Ds still in service

BOSTON SCIENTIFIC
CRT-Ds still in service¹⁷

 

BOSTON SCIENTIFIC CRT-Ds still in service

MEDTRONIC
Viva Quad XT CRT-D¹⁸

 

SMART Multi-Site Pacing (MSP)¹⁹

Based on the results of the SMART-MSP study conducted in the US with 584 patients, Boston Scientific Multi-Site Pacing is associated with improved clinical response in non-responders to CRT therapy, as well as minimal impact on battery life.

Multi-Site Pacing (MSP) has a minimal impact on battery longevity
Multi-Site Pacing (MSP) has a minimal impact on battery longevity
Economic and Environmental Gains

Higher battery capacity and device longevity not only offer clinical benefits but also result in daily savings²⁰ ranging from 0.53€ for ICD VR to 1.48€ for CRTD with MSP on.

Higher device longevity is also associated with potential decrease of GHG emission and wastage thanks to the avoidance of substitution procedures (requiring additional patient journeys, hospitalization days and surgical procedures)²¹.

Discover more on EnduraLife Battery Technology

Discover more on device longevity
Remote Patient Management

Remote Patient Management

Remote device monitoring is more relevant and useful than ever during the COVID-19 pandemic. It will help you:

  • Identify clinical events and device anomalies in patients with cardiac implantable defibrillators who's in-person visit was canceled.
  • Allow physicians to monitor disease progression remotely and to modify patients’ treatment appropriately (except for programming changes).
  • When patients feel more empowered in the remote monitoring process, they will become more invested in improving their health. Thus, we should feel confident to use remote device monitoring for patients with cardiac implantable defibrillators during the COVID-19 pandemic²².

     
LATITUDE

In the context of the Covid-19 pandemic, leveraging remote patient monitoring technology will help eliminate unnecessary patient contact, while reducing the burden on in-clinic follow-up.
 

remote patient monitoring technology
  • "Is recommended that HF patients are enrolled in a multidisciplinary HF management programme to reduce the risk of HF hospitalisation and mortality."²³
  • "Remote device management is recommended to reduce number of in-office follow-up in patients."²³
arrows

 

2021 ESC Guidelines²⁴⁻²⁵ for the management of chronic Heart Failure and implantable devices. Recommendations have now the highest level of evidence: Class 1, level of evidence A

 

In the context of the Covid-19 pandemic, leveraging remote patient monitoring technology will help eliminate unnecessary patient contact, while reducing the burden on in-clinic follow-up.

Discover Boston Scientific Patient Management solutions

Discover more on remote patient management portfolio
Remote Patient Management

Heart Failure Diagnostic

In the COVID-19 pandemic, and beyond, HeartLogic offers a personalised, remote heart failure diagnostic and monitoring solution. Using multiple, novel physiologic sensors with high sensitivity and low-alert burden, it’s validated to provide weeks of advance notice for detecting early signs of worsening heart failure.

HeartLogic is clinically validated to provide weeks of advance notice for detecting early signs of worseningheart failure²⁶

SENSITIVITY

SENSITIVITY
in detecting heart failure events²⁶

DAYS ADVANCE NOTICE

DAYS ADVANCE NOTICE
of heart failure worsening²⁶

TOTAL ALERTS

TOTAL ALERTS
per patient per year²⁶

Integration into clinical practice

In the MANAGE-HF Phase 1 Study²⁷, HeartLogic is associated with:

  • A 67% reduction in HF hospitalisation rate
  • A reduction of N-terminal pro b-type natriuretic peptide (NTproBNP) levels
MORE RAPID RECOVERY

MORE RAPID RECOVERY
of HeartLogic index

LOWER NTproBNP Levels

LOWER
NTproBNP Levels

67% REDUCTION in Hospitalisation Associated with HeartLogic

67% REDUCTION
in Hospitalisation Associated with HeartLogic

Discover how HeartLogic™ can help you in your daily practice

Discover more on heart failure diagnostic
List of products

Request a Sales Rep

Fill out a quick form and one of our sales representatives will be in touch to answer any questions you have. 

Request a Rep
Icon with envelope

Stay Updated on our Technologies

Sign up for information on our latest technologies and events.

Sign Up

References:

  1. ESC Guidance for Diagnosis and Management of CVD during the COVID-19 Pandemic: https://www.escardio.org/Education/COVID-19-and-Cardiology.
  2. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC, European Heart Journal (2021) 00, 1-128 doi:10.1093/eurheartj/ehab368.
  3. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy Developed by the Task Force on cardiac pacing and cardiac resynchronization therapy of the European Society of Cardiology (ESC) With the special contribution of the European Heart Rhythm Association (EHRA), European Heart Journal (2021) 00, 1-94 doi:10.1093/eurheartj/ehab364.
  4. Haarbo J, Hjortshoj S, Johansen J, Jorgensen O, Nielsen J, Petersen H. Device Longevity in Cardiac Resynchronization Therapy Implantable Cardioverter Defibrillators Differs Between Manufacturers: Data from the Danish ICD Registry. Presented at HRS 2014. https://ondemand.hrsonline.org/common/presentation-detail.aspx/15/35/1241/9000 . Boston Scientific = 136 patients, Medtronic = 651 patients, St. Jude Medical = 1,587 patients, Bitronik = 369 patients. Time to exchange of the device because of battery depletion or device failure recorded in the Danish ICD Registry was the endpoint. The four-year survival rate for devices in the Danish Registry study was 81.1% for Medtronic and 95.7% for Boston Scientific (P<0.01).
  5. Censi F, et al. Estimate and reporting of longevity for cardiac implantable electronic devices: a proposal for standardized criteria. Expert Rev Med Devices. 2021 Dec;18(12):1203-1208.
  6. J. Williams, R. Stevenson. Contemporary cardiac resynchronization implantable cardioverter defibrillator battery longevity in a community hospital heart failure cohort. Presented at HFSA 2014. https://www.onlinejcf.com/article.S1071-9164(14)00389-3/fulltext . Boston Scientific = 53 patients, Medtronic = 28 patients, St. Jude Medical = 10 patients. Four-year survival rate calculated using device replacements for battery depletion as indicated by ERI.
  7. Ellis CR, Dickerman DI, Orton JM, Hassan S, Good EG, Okabe T, Andruilli JA, Quan KJ, Greenspon AJ. Ampere Hour as a Predictor of Cardiac Resynchronization Defibrillator Pulse Generator Battery Longevity: A Multicenter Study. PACE 2016 doi: 10.1111/pace.12831 first published online 11-MAR-2016. The five major institutions performing the study include, at Vanderbilt University, Henry Ford Hospital, University of Michigan, Thomas Jefferson University, Cooper Health System, North Ohio Heart Center. Boston Scientific = 322 patients, Medtronic = 794 patients, St. Jude Medical = 186 patients. Five-year survival rate calculated using device replacements for battery depletion as indicated by ERI.
  8. Landolina M, Curnis A, Morani G, Vado A, Ammendola E, D’onofrio A, Stabile G, Crosato M, Petracci B, Ceriotti C, Bontempi L, Morosato M, Ballari GP, Gasparini M. Longevity of implant Cardioverter-defibrillators for cardiac resynchronization therapy in current clinical practice: an analysis according to influencing factors, device generation, and manufacturer. Europace 2015;17:1251-58. doi:10.1093/eurospace/euv109. First published online: May 8, 2015. Medtronic = 532 patients, Boston Scientific = 291 patients, St. Jude Medical = 106 patients, Biotronik = 20 patients, Sorin = 69. Five-year survival rate of latest marketed devices (between 2006 to 2010) calculated using device replacements for battery depletion as indicated by ERI.
  9. Zanon F, Martignani C, Ammendola E, Menardi E, Narducci ML, De Filippo P, Santamaria M, Campana A, Stabile G, Potenza DR, Pastore G, Iori M, La Rosa C, and Biffi M. Device Longevity in a Contemporary Cohort of ICD/CRT-D Patients Undergoing Device Replacement. Doi:10.1111/jce.12990, First published online 20-APR-2016. Comparison of device longevity by Kaplan-Meier curves of CRT-D systems extracted between March 2013 and May 2015. Medtronic = 195 patients, Boston Scientific = 157 patients, St. Jude = 72, Biotronik = 9.
  10. Provided by Dr. Ernest Lau on 04/29/15 in support of Lau E, Wilson C, Ashfield K, McNair W, McEneany D, Roberts M, Large Capacity LiMnO2 Batteries Extended CRTD Longevity in Clinical Use Compared to Smaller Capacity LiSVO Batteries Over 6 Years. Presented at HRS 2015. Medtronic = 62 patients, Boston Scientific = 27 patients, St. Jude = 66 patients. Five-year survival rate calculated using device replacements for battery depletion as indicated by ERI.
  11. von Gunten S, Schaer BA, Yap SC, Szili-Torok T, Kühne M, Sticherling C, Osswald S, Theuns DA. Longevity of implantable cardioverter defibrillators: a comparison among manufacturers and over time. Europace. 2015 Nov 25; . Epub 2015 Nov 25. Total patients = 3436.
  12. Alam MB, Munir MB, Rattan R, Adelstein E, Jain S, Saba S. Battery longevity from cardiac resynchronization therapy defibrillators: differences between manufacturers and discrepancies with published product performance reports. Europace 016;doi:10.1093/europace/euw044. First published online: 22-MAR-2016. Kaplan Meier curves depicting survival of CRT devices free from battery depletion by device manufacturer. Battery Longevity in Cardiac Medtronic = 416 patients, Boston Scientific = 173 patients, St. Jude Medical = 57patients. Previously evaluated these patients at a four-year survival rate calculated using device replacements for battery depletion as indicated by ERI. 2014; Europace (2014) 16,246-51.
  13. Shabanna Din, Shabanna, Mcgee, Rao, Archana, Wright, Jay D. Longevity of implantable cardioverter defibrillators: The impact of device manufacturer and device type on device longevity were assessed. Europace. 2015 Nov 25. Epub 2015 Nov 25. Total patients = 3436. Cardiostim Abstract 2016. Total patients = 1489
  14. Boston Scientific Data on File. February 2016.
  15. Boston Scientific CRM Product Performance Report. Data on file as of April 14, 2016
  16. Boston Scientific CRT-Ds with contemporary battery technology have 1.9 Ah. Medtronic CRT-Ds have 1.0 Ah. Amplia MRI CRT-D Surescan DTMB2D4 UK 2016 Manual pg 30. Viva XT CRT-D OUS Manual DTBA2D1 2013 page 28. DYNAGEN™ CRT-D, DYNAGEN™ X4 CRT-D, INOGEN™ CRT-D, INOGEN™ X4 CRT-D, ORIGEN™ CRT-D, ORIGEN™ X4 CRT-D Physician’s Technical Manual. Part Number: 259049-004 EN US 2014-04.
  17. Boston Scientific CRM Product Performance report. Data on file as of April 4th 2023
  18. Medtronic CRM Product Performance Report, DTBA2QQ Viva Quad XT CRT-D eSource date June 13, 2022
  19. Saba S, et al. Safety and Effectiveness of Multi-Site Pacing in Initial Non-Responders to Conventional Cardiac Resynchronization Therapy. LBCT presented at: 2021 Heart Rhythm Society; July 2021; Boston, MA.
  20. Boriani G, et al. Battery longevity of implantable cardioverter-defibrillators and cardiac resynchronization therapy defibrillators: technical, clinical and economic aspects. An expert review paper from EHRA. Europace. 2018 Dec 1;20(12):1882-1897.
  21. NHS. Care Pathways: Guidance on Appraising Sustainability - Summary. October 2015.
  22. De Larochellière, I. Nault, J. Champagne, J. Sarrazin, F. Philippon, C. Steinberg, F. Molin, G. O'Hara, K. Roy, B. Plourde, and L. Blier Can J Cardiol. 2020 Oct; 36(10): S52
  23. ESC Guidance for Diagnosis and Management of CVD during the COVID-19 Pandemic: https://www.escardio.org/Education/COVID-19-and-Cardiology.
  24. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC, European Heart Journal (2021) 00, 1-128 doi:10.1093/eurheartj/ehab368.
  25. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy Developed by the Task Force on cardiac pacing and cardiac resynchronization therapy of the European Society of Cardiology (ESC) With the special contribution of the European Heart Rhythm Association (EHRA), European Heart Journal (2021) 00, 1-94 doi:10.1093/eurheartj/ehab364.
  26. Boehmer JP, Hariharan R, Devecchi FG, et al. A Multisensor algorithm predicts heart failure events in patients with implanted devices: results from the MultiSENSE study. JACC Heart Fail. 2017 Mar;5(3):216-25.
  27. Hernandez AF, Albert N, Allen L, et al. Multiple cardiac sensors for management of heart failure (MANAGE-HF) Phase I results. Abstract presented at: European Society of Heart Failure 2021 World Congress on Acute Heart Failure: June 29-July 1, 2021. Virtual.

CAUTION:
The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device. or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries.
This material not intended for use in France.